Viatris Inc

Viatris Inc faces shareholder pressure, a negative P/E, and a shifting biosimilar landscape—yet its AI‑cardiology potential could drive new growth and stabilize its future.

Viatris’s FDA‑accepted MR‑141 could unlock a new, non‑invasive presbyopia market, diversifying earnings and boosting stock value—will it succeed?

Viatris’ UBS upgrade spotlights disciplined capital allocation, rising profitability, and a strategic pipeline poised to boost shareholder value.

Viatris Inc. (VTRS) jumps after UBS upgrades to “Buy,” citing a strong biologics pipeline and emerging‑market expansion; institutional buying signals potential upside.

Viatris Inc. faces a critical crossroads as Biocon raises capital to buy its stake, sparking debate over whether divestiture will unlock value or dilute growth prospects for the Nasdaq‑listed drugmaker.

Viatris Inc shares near 52‑week high as institutional buys and JPMorgan conference spotlight its growth strategy and pipeline, signaling potential upside for investors.

Viatris Inc. announces a $0.12 quarterly dividend, Q3 earnings outlook and a new policy initiative to improve medicine access and health system resilience.

Viatris Inc. reports strong Q2 2025 financial performance, exceeding earnings and revenue expectations, and reaffirming its financial guidance for the year.

The biosimilars market is projected to reach $88.9 billion by 2032, with Viatris Inc. well-positioned to capitalize on this growth due to its strategic focus on biosimilars and adaptability to regulatory changes.

Viatris Inc.’s stock price declined after its eye inflammation treatment failed to meet its primary endpoint in a late-stage trial, causing a setback for the pharmaceutical company.